Editor’s observe: Discover the most recent COVID-19 information and steering in Medscape’s Coronavirus Useful resource Heart.
First outcomes from a database of adults and youngsters with rheumatic and musculoskeletal ailments who’ve contracted COVID-19 might be unveiled on the upcoming digital European League Towards Rheumatism (EULAR) 2020 Congress.
The database, which is up to date weekly, will allow clinicians to match remedy and illness outcomes in sufferers and to research predictive components for poor prognoses, stated Loreto Carmona, MD, PhD, from the Musculoskeletal Well being Institute in Madrid, who’s chair of the EULAR summary choice committee.
As of Might 26, a complete of 985 sufferers from 28 collaborating international locations had been entered within the EULAR COVID-19 database, which was launched as a part of the World Rheumatology Alliance. Affected person information are categorized by components akin to high rheumatology prognosis, comorbidities, top-five COVID-19 signs, and disease-modifying anti-rheumatic drug (DMARD) remedy at time of virus an infection. Anonymized information might be shared with a global register based mostly in america.
Along with the “many questions” about which immunomodulatory medicine could make sufferers with rheumatic and musculoskeletal ailments extra susceptible to the virus, rheumatologists and sufferers additionally wish to know if any commonplace therapies can forestall the cytokine storms which might be a extreme complication of the illness, Carmona defined.
“There are additionally questions on whether or not a few of our remedies are literally masking the illness, or if we would have problems or completely different security occasions due to that,” she advised Medscape Medical Information.
“This disaster goes scarily quick,” Carmona identified. “A number of the solutions usually are not actually full and we’re nonetheless ready for some good scientific trials, however we suspect that a number of the DMARD medicines are literally taking part in a great half on this illness.”
Dangers and Safeguards
“There are actual implications for our sufferers,” stated John Isaacs, MBBS, PhD, from Newcastle College in Newcastle Upon Tyne, United Kingdom, who’s chair of the EULAR scientific program committee. “We will not make assumptions — we’ve to do trials — however the solutions to those questions will decide the life of our sufferers and the selections they make.”
“COVID-19 is a really attention-grabbing state of affairs for all kinds of causes, and never least as a result of quite a lot of the medicine we use in rheumatology are being investigated as potential remedies for extreme COVID,” he advised Medscape Medical Information.
“Which means our group has had various enter into COVID, and sufferers wish to know if they’re in danger for it or, conversely, if they could be safeguarded due to some remedy they’re receiving,” he stated.
The numerous periods scheduled for the unique assembly stay devoted to analysis on remedy choices for rheumatoid arthritis, lupus, scleroderma, and different rheumatic and musculoskeletal ailments, however a lot of the main target has naturally shifted to COVID-19, the organizers stated.
Because it has in typical years, the assembly might be dominated by analysis on rheumatoid arthritis, particularly into potential new targets. A number of noteworthy abstracts will residence in on thrombosis danger associated to inflammatory arthritis remedies, Isaacs reported.
One other summary will concentrate on opioid analgesic consumption in sufferers additionally taking TNF inhibitors. This might be attention-grabbing as a result of “I do know there’s some concern in regards to the quantity of opioid use in individuals with arthritis proper now,” he added.
European League Towards Rheumatism (EULAR) 2020 Congress.
Comply with Medscape on Fb, Twitter, Instagram, and YouTube